Organization | Nebraska Cancer Specialists

Nebraska Cancer Specialists Report issue

Academic/Hospital Phase 1 Phase 2

Organization Overview

First Clinical Trial

2006

NCT00515411

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2018

Timeline

NOW

Alternative names

Nebraska Cancer Specialists | Nebraska Cancer Specialists Methodist Estabrook Cancer Center | Nebraska Cancer Specialists; Midwest Cancer Center-Legacy | Ralph Hauke

Active Ingredients

Drugs in Phase 2 Trials (8)

aldesleukin (Proleukin) (1 trial)

cisplatin (platinol) (1 trial)

docetaxel (taxotere) (1 trial)

Filgrastim (neupogen) (1 trial)

fluorouracil (efudex) (1 trial)

leucovorin (1 trial)

pembrolizumab (keytruda) (1 trial)

sargramostim (leukine) (1 trial)

Drugs in Phase 1 Trials (1)

testosterone (delatestryl) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Adenocarcinoma (Phase 2)

Breast Neoplasms (Phase 1)

Dyspareunia (Phase 1)

Esophageal Neoplasms (Phase 2)

Melanoma (Phase 2)

Stomach Neoplasms (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 3
# of Trial APIs: 9